Ironwood Pharmaceuticals, Inc. — Cyborg Score 6/10

Strategic Profile

LINZESS delivered 11% EUTRx demand growth year-over-year in 2025, continuing to strengthen its position as the prescription market leader, surpassing 5.7 million unique patients treated since launch. In November, the FDA approved LINZESS for the treatment of IBS-C in patients aged 7 years of age and older, establishing it as the first and only prescription drug approved for this indication in patients 7-17 years old. Ironwood is in a much stronger financial position now, allowing it to leverage increased revenue and reduce debt, while remaining open to alternatives that could increase shareholder value.

Cyborg Score Rationale

The company expects full-year 2026 LINZESS U.S. net sales of $1.125 to $1.175 billion with total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million, achieving profitability with $24 million in GAAP net income and $138 million in adjusted EBITDA in 2025. However, the Altman Z-Score of -3.35 places the company in the distress zone, indicating potential financial instability, presenting execution risk despite strong commercial momentum.

Top Insights

• Ironwood settled key litigation with Ferring, removing legal overhang that could have complicated commercialization plans and clarifying intellectual property rights with $12.5 million in milestone payments and ongoing royalties
• The confirmatory Phase 3 clinical trial design of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) has been finalized with site initiations expected to begin in the second quarter of 2026
• LINZESS EUTRx demand growth of 11% for full year 2025 demonstrates sustained market momentum despite pricing pressures
• Ironwood's stronger financial position now enables leverage of increased revenue and debt reduction, shifting from pure survival mode to value creation focus

Named Competitors

• Plecanatide — GC-C agonist for IBS-C and CIC
• Linaclotide (Generic/Authorized Generics) — Generic versions of LINZESS
• GLP-1 and GLP-2 analogs — Emerging therapies in metabolic and GI disease space

Recent Developments

• (February 2026) Q4 2025 Results: Achieved full-year financial guidance with $296 million revenue, $24 million GAAP net income, $138 million adjusted EBITDA, and reiterated strong 2026 outlook
• (November 2025) FDA approval of LINZESS for pediatric IBS-C in patients aged 7 and older, establishing first and only prescription drug for this age group
• (January 2026) Settlement with Ferring regarding VectivBio subsidiary license agreement, removing legal uncertainty with $12.5 million in milestone payments
• (Q2 2026 Expected) STARS-2 Phase 3 trial site initiations begin for apraglutide in short bowel syndrome

Open the full interactive Ironwood Pharmaceuticals, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.